Eli Lilly and Novo Nordisk’s Obesity Moat Just Got Stronger

Data from their most serious competitor, Amgen, suggests the biotech won’t upstage the market leaders.

Leave a Reply

Your email address will not be published. Required fields are marked *

error: Content is protected !!